The Cancer Center strategic planning process identified the recruitment of new faculty as the most important priority for the past funding period, and it remains the most important priority for the proposed future funding period. Accordingly Cancer Center development funds have been used to support 11 new investigators, while Wistar Institute funds have underwritten pilot projects and bridged investigators who have developed research funding shortfalls due to delays in getting grants renewed. Over the past funding cycle, developmental funds have been used to support part of the direct research costs of new recruits for up to three years following their arrival. We have used $1,508,942 in developmental funds and these investigators are well on their way to establishing independent research programs. They have received funding for 14 NIH or Department of Defense grants, 25 foundation grants, and three American Cancer Society grants, among a total of almost 50 total awards, amounting to $18,266,554 in total extramural grant dollars. The Cancer Center has been able to make progress in achieving its strategic goals in the past funding period because of developmental funds provided by both the Institute and the CCSG.
| Jenkins, Russell W; Aref, Amir R; Lizotte, Patrick H et al. (2018) Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov 8:196-215 |
| Barnoud, Thibaut; Budina-Kolomets, Anna; Basu, Subhasree et al. (2018) Tailoring Chemotherapy for the African-Centric S47 Variant of TP53. Cancer Res 78:5694-5705 |
| Barbieri, Elisa; Trizzino, Marco; Welsh, Sarah Ann et al. (2018) Targeted Enhancer Activation by a Subunit of the Integrator Complex. Mol Cell 71:103-116.e7 |
| Seo, Jae Ho; Agarwal, Ekta; Bryant, Kelly G et al. (2018) Syntaphilin Ubiquitination Regulates Mitochondrial Dynamics and Tumor Cell Movements. Cancer Res 78:4215-4228 |
| Lu, Huimin; Bowler, Nicholas; Harshyne, Larry A et al. (2018) Exosomal ?v?6 integrin is required for monocyte M2 polarization in prostate cancer. Matrix Biol 70:20-35 |
| Stout, Matthew C; Narayan, Shilpa; Pillet, Emily S et al. (2018) Inhibition of CX3CR1 reduces cell motility and viability in pancreatic adenocarcinoma epithelial cells. Biochem Biophys Res Commun 495:2264-2269 |
| Hu, Xiaowen; Sood, Anil K; Dang, Chi V et al. (2018) The role of long noncoding RNAs in cancer: the dark matter matters. Curr Opin Genet Dev 48:8-15 |
| Liu, Shujing; Zhang, Gao; Guo, Jianping et al. (2018) Loss of Phd2 cooperates with BRAFV600E to drive melanomagenesis. Nat Commun 9:5426 |
| Saglam, Ozlen; Conejo-Garcia, Jose (2018) PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer. Integr Cancer Sci Ther 5: |
| Papasavvas, Emmanouil; Lada, Steven M; Joseph, Jocelin et al. (2018) Analytical ART interruption does not irreversibly change pre-interruption levels of cellular HIV. AIDS : |
Showing the most recent 10 out of 741 publications
